1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Silence Therapeutics plc

Silence Therapeutics plc

SLNCF
Silence Therapeutics plcUS flagOther OTC
1.50
USD
- -
- -
212.56MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
0.01
- -
- -
- -
0.09
0.19
0.22
0.28
0.31
- -
0.01
Basic EPS, GAAP
-0.34
-0.34
-0.15
-0.15
-0.03
-0.33
-0.34
-0.54
-0.6
-0.52
-0.49
-0.33
-0.63
-0.53
Free Cash Flow per Basic Share
-0.26
-0.3
-0.21
-0.19
-0.19
-0.31
0.03
-0.19
0.08
-0.6
-0.44
-0.49
-0.44
-0.46
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-3.36
-3.1
-2.45
-1.99
-2.18
-2.35
-2.58
-3
-3.31
-3.23
-3.8
-3.34
-3.9
-4
Tangible Book Value per Share
0.74
0.64
1.24
0.82
0.86
0.48
0.23
0.02
0.01
0.17
0.1
0.9
0.36
0.27
Basic Weighted Avg Shares
44
50
64
70
70
70
75
82
89
97
111
139
142
142
Sales/Revenue/Turnover
- -
- -
- -
1
- -
- -
- -
7
17
22
32
43
1
1
Operating Margin (%)
-7,753.85
-80,846.67
- -
-1,546.23
-89,943.75
- -
-9,317.21
-654.26
-369.02
-281.87
-203.47
-146.38
-16,055.99
-9,187.25
Depreciation Expense
- -
1
- -
- -
1
1
1
1
1
1
1
1
1
1
Net Income, GAAP
-15
-17
-10
-10
-2
-23
-26
-44
-53
-50
-54
-45
-89
-75
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-7,694.02
-73,920
- -
-1,096.1
-10,112.5
- -
-8,025.41
-594.03
-317.44
-232.44
-171.37
-104.74
-15,851.88
-8,943.86
Working Capital
32
31
78
50
58
33
36
69
96
90
81
171
105
92
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
45
43
90
67
71
44
27
12
12
27
22
134
62
49
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
142
142
142
Market Capitalization
153
211
214

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
134
119
103
Cash, Cash Equivalents & STI
102
85
70
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
17
14
10
Payables & Accruals
17
10
10
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
41.36%
112.71%
-53.51%
Free Cash Flow
-184.57%
-202.58%
-8.14%
Net Income, GAAP
107.93%
20.28%
95.57%
Sales/Revenue/Turnover
- -
27.55%
-98.71%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
16
1
1
24
43
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.14
-0.25
- -
-0.33
2025
-0.2
-0.19
-0.15
- -
-0.63
2026
-0.11
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Iain Gladstone Ross
Full Time Employees
88
Sector
Healthcare
Industry
Biotechnology
Address
72 Hammersmith Road London GL United Kingdom W14 8TH
IPO Date
Sep 25, 2012
CIK
0001479615
Website
silence-therapeutics.com
Similar Companies
Fusion Pharmaceuticals Inc. (FUSN)
Lipum AB (publ) (LIPUM.ST)
Biomm S.A. (BIOM3.SA)
BioMarin Pharmaceutical Inc. (BM8.F)
Actuate Therapeutics Inc (ACTU)
Kalaris Therapeutics Inc (KLRS)
Business
Silence Therapeutics plc (Nasdaq: SLN) develops short interfering RNA (siRNA) therapeutics harnessing the body's RNA interference mechanism to silence specific disease-associated genes, primarily targeting the liver via its proprietary mRNAi GOLD platform; key wholly owned pipeline candidates include zerlasiran (SLN360) for reducing cardiovascular risk in patients with elevated lipoprotein(a), divesiran (SLN124) for hematological disorders such as polycythemia vera, SLN548 for complement-mediated diseases, and earlier-stage programs like SLN312, SLN-140 and SLN-HAN-1/2; the company licenses its platform for partnered programs across cardiovascular, rare hematological, oncology and other areas. Founded in 1994 and headquartered at 12 Hammersmith Grove, London W6 7AP, United Kingdom, Silence Therapeutics maintains operations in the United States (Hoboken, New Jersey) and Germany (Berlin), employing approximately 120 people while generating revenue from research collaborations, royalties and milestones. Recent developments include reporting $43.3 million in full-year 2024 revenues (up from prior year, driven by collaborations with AstraZeneca, Hansoh Pharma and royalties from Alnylam), advancing divesiran to Phase 2 enrollment in polycythemia vera (with Phase 1 follow-up completed and data presentations planned for 2025), preparing zerlasiran for Phase 3 cardiovascular outcomes pending a partner (with FDA positive feedback received and discussions ongoing to extend cash runway into 2027), planning a Phase 1 start for SLN548 in second-half 2025, continuing a Phase 1 study of SLN312 (licensed to AstraZeneca) and regaining global rights to three preclinical targets after Hansoh Pharma opted out of further development.